Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Voon, V.
Right arrow Articles by Miyasaki, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Voon, V.
Right arrow Articles by Miyasaki, J.
NEUROLOGY 2006;66:1750-1752
© 2006 American Academy of Neurology
Brief Communications

Prospective prevalence of pathologic gambling and medication association in Parkinson disease

V. Voon, MD, K. Hassan, MD, M. Zurowski, MD, S. Duff-Canning, PhD, M. de Souza, MBBS, S. Fox, MD, PhD, A. E. Lang, MD and J. Miyasaki, MD

From the Human Motor Control Section (V.V.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and Department of Psychiatry (V.V., M.Z., M.D.) and Division of Neurology (K.H., S.D.-C., S.F., A.E.L., J.M.), Toronto Western Hospital, Toronto, Canada.

Address correspondence and reprint requests to Dr. Valerie Voon, Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Building 10, Room 5S213, 10 Center Drive, Bethesda, MD 20892-1428; e-mail: voonv{at}ninds.nih.gov

The authors prospectively screened 297 patients with Parkinson disease (PD), who attended a tertiary clinic, using a modified South Oaks Gambling Scale. Lifetime prevalence of pathologic gambling (PG) was 3.4% and on any dopamine agonist was 7.2%. PG was associated with earlier PD onset and with dopamine agonists but not with agonist subtype or doses. We found no association with a potent D3 receptor agonist.

Disclosure: The authors report no conflicts of interest.

Received December 9, 2005. Accepted in final form February 17, 2006.




This article has been cited by other articles:


Home page
 NeurologyHome page
C. W. Olanow, M. B. Stern, and K. Sethi
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Neurology, May 26, 2009; 72(21_Supplement_4): S1 - S136.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
T. D. L. Steeves, J. Miyasaki, M. Zurowski, A. E. Lang, G. Pellecchia, T. Van Eimeren, P. Rusjan, S. Houle, and A. P. Strafella
Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study
Brain, May 1, 2009; 132(5): 1376 - 1385.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
J. M. Bostwick, K. A. Hecksel, S. R. Stevens, J. H. Bower, and J. E. Ahlskog
Frequency of New-Onset Pathologic Compulsive Gambling or Hypersexuality After Drug Treatment of Idiopathic Parkinson Disease
Mayo Clin. Proc., April 1, 2009; 84(4): 310 - 316.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A H Evans, A D Lawrence, and A J Lees
Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, March 1, 2009; 80(3): 267 - 272.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. E. Lang
When and how should treatment be started in Parkinson disease?
Neurology, February 17, 2009; 72(7_Supplement_2): S39 - S43.
[Abstract] [Full Text] [PDF]

Home page
 Cogn Affect Behav NeurosciHome page
S. B. Floresco, J. R. St. Onge, S. Ghods-Sharifi, and C. A. Winstanley
Cortico-limbic-striatal circuits subserving different forms of cost-benefit decision making
Cogn Affect Behav Neurosci, December 1, 2008; 8(4): 375 - 389.
[Abstract] [PDF]

Home page
 Br Med BullHome page
C. A. Davie
A review of Parkinson's disease
Br. Med. Bull., June 1, 2008; 86(1): 109 - 127.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
V. Voon and S. H. Fox
Medication-Related Impulse Control and Repetitive Behaviors in Parkinson Disease
Arch Neurol, August 1, 2007; 64(8): 1089 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
S. H Wong and M. J Steiger
Pathological gambling in Parkinson's disease
BMJ, April 21, 2007; 334(7598): 810 - 811.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
R. B. Dewey Jr, S. C. Reimold, and P. E. O'Suilleabhain
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonists in Parkinson Disease
Arch Neurol, March 1, 2007; 64(3): 377 - 380.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
V. Voon, T. Thomsen, J. M. Miyasaki, M. de Souza, A. Shafro, S. H. Fox, S. Duff-Canning, A. E. Lang, and M. Zurowski
Factors Associated With Dopaminergic Drug-Related Pathological Gambling in Parkinson Disease
Arch Neurol, February 1, 2007; 64(2): 212 - 216.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
V. Voon, K. Hassan, M. Zurowski, M. de Souza, T. Thomsen, S. Fox, A. E. Lang, and J. Miyasaki
Prevalence of repetitive and reward-seeking behaviors in Parkinson disease
Neurology, October 10, 2006; 67(7): 1254 - 1257.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
S. H. Fox, N. P. Visanji, T. H. Johnston, J. Gomez-Ramirez, V. Voon, and J. M. Brotchie
Dopamine Receptor Agonists and Levodopa and Inducing Psychosis-Like Behavior in the MPTP Primate Model of Parkinson Disease.
Arch Neurol, September 1, 2006; 63(9): 1343 - 1344.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.